Nerve Supplement Guide: What Has Actually Been Trialled

Numbness, burning, tingling and pins and needles are a symptom with a long list of causes behind it, and the list is the reason a supplement is the wrong first move.

The NINDS overview of peripheral neuropathy sets out the range: diabetes, alcohol, vitamin deficiency and vitamin excess, thyroid disease, kidney disease, autoimmune conditions, infections, inherited disorders, injury and a long list of medicines including several chemotherapies. The NIDDK page on diabetic neuropathy describes the commonest single cause in the United States, and the MedlinePlus overview is the plainest short version of the same ground.

Two of those causes are treatable in a way no capsule touches. A B12 deficiency is corrected by replacing B12. A thyroid problem is corrected by treating the thyroid. Getting either diagnosis takes a blood test and getting neither of them takes a year of guessing.

There is also a cause that runs the other way, and it matters in a guide about supplements. Vitamin B6 in excess causes a sensory neuropathy of its own, which is one of the few situations where a supplement shelf is part of the problem rather than a response to it.

The 2024 review of current US guidelines for painful diabetic peripheral neuropathy is the clearest picture of what the treatment ladder actually looks like when a cause is known. Reading it is a useful corrective to a supplement aisle, because the things on it are not what is on the aisle.

Three, and they are the ones a reader should know by name before comparing any label in this category. Each has a dose its trials used and an outcome they measured.

Three names, three doses, and one observation that does most of the work in this guide: 600 mg, 300 to 600 mg and 2,000 mg are large amounts. A capsule that carried all three at their trial doses would weigh more than three grams a day, which is four or five capsules of powder before anything else is added.

That is why so many labels in this category do not carry them. It is not a conspiracy; it is arithmetic about what fits in a capsule and what it costs to put there.

A different literature, and the most useful thing to know about it is the subject each one was studied for, which is usually not nerves.

Nine botanicals, and not one of those trial columns says nerves. That is the single most useful fact in this guide.

The sources for every row are in the reference list below: the six-month Tongkat Ali trial, the Epimedium prenylflavonoid trial, the JAMA Garcinia trial, the bitter melon prediabetes trial, the cinnamon dose-response meta-analysis, the vinegar post-meal study, the wild yam trial, the Cochrane lysine review and the raspberry ketone mouse study.

A reader can draw one of two conclusions from that table and both are defensible. The first is that these plants have not been tested for nerve symptoms and therefore should not be sold for them. The second is that several of them have glucose literatures, diabetes is the commonest cause of peripheral neuropathy in the United States, and a glucose effect is at least a coherent story.

The second is a hypothesis rather than a finding, and the distance between those two words is what this guide exists to hold open. A rat study of bitter melon in experimental diabetic neuropathy is the closest thing to a bridge, and it is a rat study.

Because a dietary supplement may make structure-and-function claims and may not make disease claims, and every phrase on every carton in this aisle is shaped by that line.

Knowing that changes how a shelf reads. Three bottles printing the same three support lines have not made three equivalent claims; they have made no claims at all, in identical words, because those are the words available.

What separates them is the panel underneath, which is the subject of the second guide.